Abstract:Abstract:ObjectiveTo analyze the therapeutic regimens and effects of neuroendoscopic surgery for skull base chordoma.MethodsClinical data of 30 patients with skull base chordoma treated with neuroendoscopic surgery in our department from Jan. 2014 to Jan. 2019 were analyzed retrospectively. The analyzed data included clinical symptoms, imaging characteristics, selection of surgical approaches, surgical essentials and complications.Results34 operations were performed in all the 30 cases. 17 gross total resections (GTR) were achieved in 16 cases (16/30, 53.3%), 8 subtotal resections (STR) in 8 (8/30, 26.7%), and 9 most part resections in 6 (6/30, 20%). One patient died of perioperative infection. The clinical symptoms were relieved in 25 cases (25/30, 80%), not significantly improved in 4 (4/30, 13.3%), and aggravated in one (1/30, 3.3%), with occurrence of new neurological dysfunction in 2 (2/30, 6.7%). Adjuvant radiotherapies were applied to 13 patients, including conformal radiotherapy in 6, gamma knife radiotherapy in 4, and proton knife radiotherapy in 3. Of the 25 cases under followup, 18 patients had no tumor progression after operation (18/25, 72%) with progressionfree survival (PFS) of 6 to 50 months (average 15.7 months). Tumor recurrence occurred in 7 cases (7/25, 28%) with PFS of 5 to 39 months (average 14.1 months). 2 patients died of secondary pulmonary infection. Tumor recurrence occurred in 2 of the 13 patients with adjuvant radiotherapy, and in 5 of the 12 patients without adjuvant radiotherapy. Comparison of the survival curves between the two groups indicated better PFS in the patients with adjuvant radiotherapy (P=0.038).ConclusionsNeuroendoscopic resection of skull base chordoma has the characteristics of wide vision, close and multiangle observation, and the advantages of high total resection rate and high safety. Postoperative adjuvant radiotherapy can prolong the tumorfree survival of patients with skull base chordoma.